Novartis’ chimeric antigen receptor T cell therapy (CAR-T) was supported and approved unanimously (10-0) on July 12th by the U.S. FDA Advisory Committee experts. This vote marks the key milepost of thisRead More…
On July 12, FDA experts will discuss whether CAR-T CTL019 can be on the market, which is an assessment of the CTL019 Biologics License Application (BLA) submitted by Novartis and will evaluate the dataRead More…
CAR-T (T cell chimeric antigen receptor), as an immune cell therapy has attracted worldwide attention including academics, doctors, patients, and investors. However, what’s CAR-T exactly? What’s the background of it? What’s the currentRead More…
Chimeric antigen receptor (CAR) T cells have hit the cancer immunotherapy area in the past few years. ‘A CAR therapy for cancer, using a technique called adoptive cell transfer, has been approvedRead More…
CAR-T is chimeric antigen receptor T cell immunotherapy, which modifies T cell receptor by CAR and transforms it into the scFV segment in the binding domain of monoclonal antibodies. A classic CAR-TRead More…
CAR-T, Chimeric Antigen Receptor T-Cell Immunotherapy, is the most effective treatment of malignant tumors. Similar to other immunotherapy, its basic principle is to remove cancer cells in the use of the patient’s own immuneRead More…
On March 29, 2017, Novartis announced that the US FDA has issued a priority review for its CAR-T therapy CTL019 (tisagenlecleucel-T) biologics licensing application. The indications of CTL019 was recurrent or refractory B-cellRead More…